Stephanie Samuels, MD
DownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Titles
Assistant Professor
Appointments
Pediatric Endocrinology & Diabetes
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- Weill Cornell Medical College (2012)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Stephanie Samuels's published research.
Publications Timeline
A big-picture view of Stephanie Samuels's research output by year.
Michelle Van Name, MD
Pamela Hu, MD
Alfonso Galderisi, MD, PhD
Kate Weyman
Nicola Santoro, MD, PhD
Daniel F Vatner, MD, PhD
10Publications
17Citations
Publications
2024
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchAltmetricConceptsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian follow-upMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchCitationsConceptsGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of HealthComparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretionRising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States
Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNonalcoholic fatty liver diseaseOral glucose tolerance testGlucose tolerance testProton density fat fractionLiver diseaseSars-Cov-2 pandemicTolerance testSeverity of NAFLDMagnetic resonance imaging-derived proton density fat fractionFrequency-matched control groupIntrahepatic fat contentCommon liver diseaseFatty liver diseasePediatric obesity clinicVisceral adipose tissueGlobal pandemicNAFLD prevalenceObesity clinicMetabolic severityInsulin secretionAdipose tissueControl groupObesityPatient careHealth differences
2022
Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity
Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPediatric weight management interventionsHealthy lifestyle interventionReal-world effectivenessWeight management interventionsLifestyle interventionChildhood obesityClinical effectivenessFemale sexInsurance categoriesBMIp95Mixed-effects modelsGreater reductionBMIBright bodiesInterventionSexParticipantsManagement interventionsObesityReal-world adaptationYearsTrialsMechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach
Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOral glucose tolerance testΒ-cell functionΒ-cell glucose sensitivityInsulin sensitivityGenetic risk profileMultiple oral glucose tolerance testsDifferent genetic risk profilesRisk profileMin oral glucose tolerance testLatent class trajectory analysisGlucose tolerance testImpaired insulin sensitivityPlasma glucose responseGlucose sensitivityClass 3Model-predicted probabilityClass 1Tolerance testProgressive impairmentMultiethnic cohortGlucose responseLongitudinal changesObesityTransient reductionInsulin kinetics342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth
GALDERISI A, LAT J, SAMUELS S, PIERPONT B, VAN NAME M, SANTORO N, CAPRIO S. 342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth. Diabetes 2022, 71 DOI: 10.2337/db22-342-or.Peer-Reviewed Original ResearchConceptsBeta-cell functionIncretin effectInsulin sensitivityInsulin secretionCell functionFirst-phase insulin secretionIsoglycemic intravenous glucose infusionLongitudinal declineReduced β-cell functionEarly insulin secretionLower insulin sensitivityIntravenous glucose infusionΒ-cell functionOral minimal modelIncretin groupsObese youthGlucose infusionRelative increaseNational InstituteTertileLongitudinal trajectoriesObesitySecretionGlucoseGroup
2021
The Yale Bright Bodies Lifestyle Intervention Program: An Intensive Lifestyle Intervention for Obese Children and Adolescents With and Without T2D
Savoye M, Rose P, Samuels S, Tamborlane W, Caprio S, Van Name M. The Yale Bright Bodies Lifestyle Intervention Program: An Intensive Lifestyle Intervention for Obese Children and Adolescents With and Without T2D. Contemporary Endocrinology 2021, 203-216. DOI: 10.1007/978-3-030-64133-7_19.ChaptersConceptsLifestyle intervention programLifestyle interventionObese childrenIntensive lifestyle intervention programPediatric lifestyle interventionCornerstone of treatmentIntensive lifestyle interventionPrevalence of obesityType 2 diabetesIntervention programsOverproduction of insulinInsulin sensitivityClinical studiesBody weightCaregiver supportT2DChildrenInterventionPrevalenceAdolescentsGlycemiaObesityDiabetesT2D.DietitiansCurrent Treatment of Pediatric Type 2 Diabetes
Samuels S, Van Name M, Guandalini C, Tamborlane W, Caprio S. Current Treatment of Pediatric Type 2 Diabetes. Contemporary Endocrinology 2021, 191-202. DOI: 10.1007/978-3-030-64133-7_18.Chapters
2020
Fatty liver, irrespective of ethnicity, is associated with reduced insulin clearance and insulin resistance in obese youths
Trico D, Galderisi A, Galuppo B, Pierpont B, Samuels S, Santoro N, Caprio S. Fatty liver, irrespective of ethnicity, is associated with reduced insulin clearance and insulin resistance in obese youths. Endocrine Abstracts 2020 DOI: 10.1530/endoabs.70.aep256.Peer-Reviewed Original ResearchCitations
Clinical Trials
Current Trials
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
HIC ID2000031181RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsPathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
HIC ID2000028731RoleSub InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsGenderBothAge12 years - 18 yearsThe Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
HIC ID1604017607RoleSub InvestigatorPrimary Completion Date05/01/2023Recruiting ParticipantsGenderBothAge12 years - 30 yearsStudy to investigate adipocyte cell and lipid turnover in obese adolescents
HIC ID1503015459RoleSub InvestigatorPrimary Completion Date05/01/2025Recruiting ParticipantsGenderBothAge12 years - 21 yearsPrevalence of Carbohydrate Intolerance in Lean and Obese Children
HIC ID9909011190RoleSub InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsGenderBothAge8 years - 18 years
Clinical Care
Overview
Clinical Specialties
Pediatric Endocrinology & Diabetes
Fact Sheets
Psychological Assessment of Children
Learn More on Yale MedicineChild Development
Learn More on Yale MedicineVitamin D Deficiency
Learn More on Yale MedicineHypercholesterolemia (High Cholesterol)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.